Yili Ding

Title: Yili Ding: Innovator in Antiviral Agents

Introduction

Yili Ding is a notable inventor based in Fountain Valley, California. He has made significant contributions to the field of antiviral agents, holding two patents that showcase his innovative work. His research focuses on developing compounds that can serve as therapeutic agents, particularly in combating viral infections.

Latest Patents

Yili Ding's latest patents include "2-beta-modified-6-substituted adenosine analogs and their use as antiviral agents." This patent describes various 2'-beta-methyl-6-substituted adenosine analogs, which are prepared using conventional and combinatorial library approaches. These compounds are particularly useful as therapeutic agents and have potential applications as antiviral agents. Another significant patent is "Inhibitors for de novo-RNA polymerases and methods of identifying targets for same." This invention involves a polymerase inhibitor that has a first moiety coupled to a second moiety via an optional linker. The first moiety binds to an initiation nucleotide binding site of a polymerase, forming at least two hydrogen bonds with an RNA template strand associated with the polymerase. The second moiety comprises a compound that binds to a site proximal to the nucleotide binding site of the polymerase, thereby increasing the affinity of the polymerase inhibitor to the polymerase.

Career Highlights

Throughout his career, Yili Ding has worked with prominent companies in the pharmaceutical industry, including Valeant Pharmaceuticals North America and Ribapharm Inc. His experience in these organizations has contributed to his expertise in developing innovative antiviral therapies.

Collaborations

Yili Ding has collaborated with several professionals in his field, including Haoyun An and Zhi Hong. These collaborations have likely enhanced his research and development efforts in creating effective antiviral agents.

Conclusion

Yili Ding's contributions to the field of antiviral agents through his patents and collaborations highlight his role as an innovator in the pharmaceutical industry. His work continues to pave the way for new therapeutic options in combating viral infections.